-
Alogliptin, sold
under the
brand names Nesina and Vipidia, is an oral anti-diabetic drug in the DPP-4
inhibitor (gliptin) class. Like
other members of...
- Kowa Company, Ltd.)
Teneligliptin (approved in ****an as
Tenelia in 2012)
Alogliptin (FDA
approved 2013 as Nesina/ Vipidia,
marketed by
Takeda Pharmaceutical...
- any loss of DPP-4 inhibition.
Alogliptin was
discovered when
quinazolinone was
replaced with a pyrimidinedione.
Alogliptin has
shown excellent inhibition...
- FDA
Approved July 2009
linagliptin (Tradjenta) FDA
Approved May 2, 2011
alogliptin septagliptin teneligliptin gemigliptin (Zemiglo) DPP-4
inhibitors lowered...
-
antigens (specifically CD26). Chemically, it is a
fluorinated derivative of
alogliptin.
Formulated as the salt
trelagliptin succinate, it was
approved for use...
-
alogliptin A10BD10
Metformin and
saxagliptin A10BD11
Metformin and
linagliptin A10BD12
Pioglitazone and
sitagliptin A10BD13
Metformin and
alogliptin A10BD14...
-
Lixisenatide Orforglipron†
Semaglutide Taspoglutide† DPP-4 inhibitors/"gliptins"
Alogliptin Anagliptin Evogliptin Garvagliptin Gemigliptin Gosogliptin Linagliptin...
-
Lixisenatide Orforglipron†
Semaglutide Taspoglutide† DPP-4 inhibitors/"gliptins"
Alogliptin Anagliptin Evogliptin Garvagliptin Gemigliptin Gosogliptin Linagliptin...
-
Lixisenatide Orforglipron†
Semaglutide Taspoglutide† DPP-4 inhibitors/"gliptins"
Alogliptin Anagliptin Evogliptin Garvagliptin Gemigliptin Gosogliptin Linagliptin...
-
contributed to the
development of
multiple FDA-approved medicines,
including alogliptin, trelagliptin,
Zemiglo (Zemdi), Zemdri, and Kybella.
David earned an A...
